Press Releases

• Nov 25, 2019 Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors
• Oct 11, 2019 Rezolute Management to Present at 2019 BIO Investor Forum Conference
• Aug 5, 2019 Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference
• Jul 24, 2019 Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
• Jan 7, 2019 Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
• May 16, 2018 Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
• Apr 9, 2018 Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
• Apr 4, 2018 Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
• Apr 3, 2018 Rezolute, Inc. Announces Close of Convertible Note Financing
• Dec 26, 2017 UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC